Evaluating only Relievet’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Regulation.
Key Events Timeline
FOUNDING
Bo Goulet bootstraps Relievet to sell CBD pet wellness oils following 2018 Farm Bill hemp legalization.
PRODUCT LAUNCH
Revenue reaches approximately $5M annually; products listed on Chewy, Amazon, and direct-to-consumer channels.
REGULATORY ACTION
FDA declares CBD not recognized as safe for human or animal food products; retailer delistings begin immediately.
SHUTDOWN
Chewy and Amazon remove all CBD pet products; Relievet loses 60% of sales channels; operations cease.
Full Analysis
Free · no account needed
Documented cause
Relievet sold CBD-based pet wellness products founded by Bo Goulet in 2018, capitalizing on the post-2018 Farm Bill CBD boom. The company bootstrapped to approximately $5M annual revenue by 2021 selling hemp-derived CBD oils for dogs and cats. However, the FDA issued a December 2022 statement declaring CBD not safe for human or animal food use, triggering retailer delistings. Chewy and Amazon removed CBD pet products in Q1 2023. Relievet lost 60% of its sales channels and could not sustain operations through the regulatory freeze.
Lesson
“Pet wellness businesses built on unregulated ingredients face existential FDA regulatory risk at any moment.”